Advertisement
Loading...

Xuanzhubio-b

2575.HKHKSE
Healthcare
Drug Manufacturers - Specialty & Generic
HK$17.90
HK$0.24(1.36%)
Hong Kong Market is Open • 13:34

Xuanzhubio-b Fundamental Analysis

Xuanzhubio-b (2575.HK) shows weak financial fundamentals with a PE ratio of -15.37, profit margin of -18.49%, and ROE of -53.85%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

PEG Ratio-0.15
Current Ratio2.06

Areas of Concern

ROE-53.85%
Operating Margin-18.73%
Cash Position3.17%
We analyze 2575.HK's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -1763.6/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-1763.6/100

We analyze 2575.HK's fundamental strength across five key dimensions:

Efficiency Score

Weak

2575.HK struggles to generate sufficient returns from assets.

ROA > 10%
-47.37%

Valuation Score

Excellent

2575.HK trades at attractive valuation levels.

PE < 25
-15.37
PEG Ratio < 2
-0.15

Growth Score

Weak

2575.HK faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Excellent

2575.HK maintains a strong and stable balance sheet.

Debt/Equity < 1
0.00
Current Ratio > 1
2.06

Profitability Score

Weak

2575.HK struggles to sustain strong margins.

ROE > 15%
-5385.27%
Net Margin ≥ 15%
-18.49%
Positive Free Cash Flow
No

Key Financial Metrics

Is 2575.HK Expensive or Cheap?

P/E Ratio

2575.HK trades at -15.37 times earnings. This suggests potential undervaluation.

-15.37

PEG Ratio

When adjusting for growth, 2575.HK's PEG of -0.15 indicates potential undervaluation.

-0.15

Price to Book

The market values Xuanzhubio-b at 9.11 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

9.11

EV/EBITDA

Enterprise value stands at -16.68 times EBITDA. This is generally considered low.

-16.68

How Well Does 2575.HK Make Money?

Net Profit Margin

For every $100 in sales, Xuanzhubio-b keeps $-18.49 as profit after all expenses.

-18.49%

Operating Margin

Core operations generate -18.73 in profit for every $100 in revenue, before interest and taxes.

-18.73%

ROE

Management delivers $-53.85 in profit for every $100 of shareholder equity.

-53.85%

ROA

Xuanzhubio-b generates $-47.37 in profit for every $100 in assets, demonstrating efficient asset deployment.

-47.37%

Following the Money - Real Cash Generation

Operating Cash Flow

Xuanzhubio-b generates limited operating cash flow of $-104.67M, signaling weaker underlying cash strength.

$-104.67M

Free Cash Flow

Xuanzhubio-b generates weak or negative free cash flow of $-105.22M, restricting financial flexibility.

$-105.22M

FCF Per Share

Each share generates $-0.20 in free cash annually.

$-0.20

FCF Yield

2575.HK converts -1.13% of its market value into free cash.

-1.13%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-15.37

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.15

vs 25 benchmark

P/B Ratio

Price to book value ratio

9.11

vs 25 benchmark

P/S Ratio

Price to sales ratio

284.15

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.002

vs 25 benchmark

Current Ratio

Current assets to current liabilities

2.06

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.54

vs 25 benchmark

ROA

Return on assets percentage

-0.47

vs 25 benchmark

ROCE

Return on capital employed

-0.56

vs 25 benchmark

How 2575.HK Stacks Against Its Sector Peers

Metric2575.HK ValueSector AveragePerformance
P/E Ratio-15.3728.95 Better (Cheaper)
ROE-53.85%747.00% Weak
Net Margin-1848.97%-49219.00% (disorted) Weak
Debt/Equity0.000.39 Strong (Low Leverage)
Current Ratio2.063.98 Strong Liquidity
ROA-47.37%-19945.00% (disorted) Weak

2575.HK outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Xuanzhubio-b's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ